echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Brit J Heamatol: Prediction of hemorrhage during vitamin K antagonist treatment in venous thrombosis clinic patients

    Brit J Heamatol: Prediction of hemorrhage during vitamin K antagonist treatment in venous thrombosis clinic patients

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bleeding is the most common complication associated with anticoagulant therapy, but its characteristics are not yet fully defined and important for risk/benefit assessmentIn a recent study published in the Journal of the British Journal of Blood System Diseases, researchers used the UK Clinical Practice Study Data Chain to develop a risk stratified score to predict bleeding associated with vitamin K antagonism (VKA) therapy in patients with vein thrombosis embolism (VTE)outpatient hemorrhage events include large haemorrhage within 90 days of starting vKA and clinically related non-hemorrhage (CRNMB-H) requiring hospitalizationThe researchers developed a scoring scheme for predicted bleeding through sub-risk ratios, which were validated using cross-validation and represented by C-statisticsthe team consisted of 10010 first-time VTE patients treated with VKA, with an average age of 62.2 yearsBetween 2008 and 2016, the study recorded 167 cases of haemorrhage (1.7 per cent), or 7.4 per 100 people per yearIndependent predictors of community-acquired hemorrhage include active cancer, trauma/surgery, men, dementia, liver disease, anemia, history of bleeding, cerebrovascular, kidney and chronic lung disease, VTE performance of pulmonary embolism and age over 75For the total C statistic for haemorrhage was 0.68 (95% CI was 0.60-0.76) and 0.75 (0.60-0.88), for CRNMB-H it was 0.65 (0.55-0.75), and was higher than other risk scores for the study population, the risk score developed by the institute can identify patients with a significant risk of bleeding in outpatients, especially those at risk of haemorrhage
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.